ReviewTaiwan journal of ophthalmology
Innovations in brachytherapy.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trichiasis as a clinical manifestation of subconjunctival epithelioid hemangioendothelioma: a rare case report.Frontiers in oncology · 2025Article
- Ocular oncology: Rare and amazing.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plaque brachytherapy plays an essential role in the management of intraocular tumors, allowing localized treatment while minimizing damage to surrounding structures. Since the earliest reports of sutured radon seeds used in glioma treatment in the 1920s, plaque brachytherapy in the field of ocular oncology has continued to expand and improve significantly. Today, a wide variety of ocular conditions, both oncologic and not can be treated using plaque brachytherapy. Continued innovations have also improved clinical safety and efficacy for both providers and patients alike. The use of new radioisotopes, combined with continued refinement in plaque design and applicators alongside radiation dose planning are some of novel methods used to maximize coverage and reduce radiation exposure to critical eye structures. In this paper, we will discuss promising future developments that will continue to revolutionize treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.